Mostrando 1 - 20 Resultados de 25 Para Buscar '"Z Cars"', tiempo de consulta: 1.54s Limitar resultados
  1. 1
    “…We evaluated the utility of a non-invasive, serial (89)Zr-oxine PET imaging to assess optimal dosing for huLym-1-A-BB3z-CAR T-cell directed to Lym-1-positive Raji lymphoma xenograft in NOD Scid-IL2Rgamma(null) (NSG) mice. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Spatio-temporal biodistribution of (89)Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model
  2. 2
    “…However, electric cell-substrate impedance sensing revealed that the CD28.41BB.z CAR performs worst in sequential short-term elimination of adherent tumor cells, while the .z CAR is superior to all others. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells
  3. 3
    “…We selected the 28.28z CAR since CAR expression on the cell surface of transduced T cells was higher in comparison to 8.28z CARs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing
  4. 4
    “…A single dose of MUC28z CAR T cells significantly reduced TNBC tumor growth in a xenograft model. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
  5. 5
    “…Interestingly, CD19.79A.40z CAR- and CD19.BBz CAR-T cells were enriched in almost similar pathways. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Enrichment of T-cell proliferation and memory gene signatures of CD79A/CD40 costimulatory domain potentiates CD19CAR-T cell functions
  6. 6
    “…However, due to the poor persistence of NKG2D(z) CAR-T cells, their therapeutic effect is not obvious. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells
  7. 7
    “…However, severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occurred in the 28z CAR-T cohort, resulting in the termination of further evaluation of 28z CAR-T. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma
  8. 8
    “…Here, we optimized and validated a non-viral genetic modification platform based on Sleeping Beauty (SB) transposons delivered with minicircles to express CD19-28z.CAR and CRISPR-Cas9 ribonucleoparticles to inactivate allogeneic TCRs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy
  9. 9
    “…T cells engineered with a chimeric antigen receptor (CAR) comprising human epidermal growth factor receptor 2 (EGFR2/HER2)-binding extracellular region and intracellular regions of CD96 and CD3ζ (4D5-96z CAR-T cells) were less effective in suppressing the growth of HER2-expressing tumor cells in vitro and in vivo compared with counterparts bearing CAR that lacked CD96 endodomain (4D5-z CAR-T cells). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    An Inhibitory Role for Human CD96 Endodomain in T Cell Anti-Tumor Responses
  10. 10
    “…Following RNA electroporation, C4-27z and C4opt-27z CAR expression is initially ubiquitous but progressively declines across T cell populations. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor
  11. 11
    “…In vivo, differentiated CD28.z CAR T cells also had the greatest antitumor activity, resulting in complete response. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models
  12. 12
    “…Our results provide biological explanations for the dramatic anti-tumor effects of CD19 CARs and for the observations that CD19.BBz CAR T cells are more persistent than CD19.28z CAR T cells in clinical trials.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors
  13. 13
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Sialic Acid—Modified Nanoparticles—New Approaches in the Glioma Management—Perspective Review
  14. 14
    “…Deletion of exhaustion-specific candidate enhancers of PDCD1 suppress the expression of PD-1 in an in vitro model of T cell dysfunction and in HA-28z CAR T cells, suggesting enhancer editing as a path forward in improving cancer immunotherapy.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dynamic chromatin regulatory landscape of human CAR T cell exhaustion
  15. 15
    “…We assessed clinical products from an ongoing clinical trial utilizing CD19–28z CAR-T cells from patients with acute lymphoblastic leukemia. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose
  16. 16
    por Zhang, Li-Na, Song, Yongping, Liu, Delong
    Publicado 2018
    “…The data from long-term follow-up of a single-center phase I study of 19-28z CAR-T cell therapy for adult R/R ALL were just published. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
  17. 17
    “…Then, cells were transduced with an NKG2D-4-1BB-CD3z-CAR. CAR-NKAE cells exhibited no evidence of genetic abnormalities. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
  18. 18
    por Spiegel, Jay Y., Patel, Shabnum, Muffly, Lori, Hossain, Nasheed M., Oak, Jean, Baird, John H., Frank, Matthew J., Shiraz, Parveen, Sahaf, Bita, Craig, Juliana, Iglesias, Maria, Younes, Sheren, Natkunam, Yasodha, Ozawa, Michael G., Yang, Eric, Tamaresis, John, Chinnasamy, Harshini, Ehlinger, Zach, Reynolds, Warren, Lynn, Rachel, Rotiroti, Maria Caterina, Gkitsas, Nikolaos, Arai, Sally, Johnston, Laura, Lowsky, Robert, Majzner, Robbie G., Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Sidana, Surbhi, Shizuru, Judith, Weng, Wen-Kai, Mullins, Chelsea, Jacob, Allison, Kirsch, Ilan, Bazzano, Magali, Zhou, Jing, Mackay, Sean, Bornheimer, Scott J., Schultz, Liora, Ramakrishna, Sneha, Davis, Kara L., Kong, Katherine A., Shah, Nirali N., Qin, Haiying, Fry, Terry, Feldman, Steven, Mackall, Crystal L., Miklos, David B.
    Publicado 2021
    “…To prevent relapse with CD19(−) or CD19(lo) disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial (NCT03233854) of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
  19. 19
    “…Importantly, self-enriched NKG2D CAR T cells effectively recognized and eliminated TNBC cell lines in vitro, and adoptive transfer of T cells expressing NKG2D CARs with CD27 or 4-1BB specifically enhanced NKG2D CAR surface expression, T cell persistence, and the regression of established MDA-MB-231 TNBC in vivo. NKG2D-z CAR T cells lacking costimulatory domains were less effective, highlighting the need for costimulatory signals. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells
  20. 20
    “…METHODS: To evaluate the safety and efficacy of antigen-specific CAR T cells, murine B7-H3-CAR T cells were generated using retroviral particles encoding 2(nd) generation B7-H3-specific CD28.z CAR. Expansion, persistence, and anti-tumor activity were evaluated in vitro and in vivo. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
Herramientas de búsqueda: RSS